Recommended treatment protocols to improve management of hypertension globally: A statement by resolve to save lives and the world hypertension league (WHL)

Journal of Clinical Hypertension

Volumn 20, Issue 5, 2018, Pages 829-836

  Jaffe, Marc G ^a,b   Frieden, Thomas R ^a   Campbell, Norman R C ^c   Matsushita, Kunihiro ^d   Appel, Lawrence J ^e   Lackland, Daniel T ^f,g   Zhang, Xin Hua ^g,h   Muruganathan, Arumugam ^i,j   Whelton, Paul K ^k  

^a Vital Strategies   (United States)

^b KAISER PERMANENTE   (United States)

^c UNIVERSITY OF CALGARY   (Canada)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^g World Hypertension League   (United States)

^h WHO China   (China)

ⁱ Tamilnadu Dr MGR Medical University   (India)

^j American College of Physicians India Chapter   (India)

^k TULANE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CHLORTALIDONE; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; INDAPAMIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; NIFEDIPINE; OLMESARTAN; TELMISARTAN; VALSARTAN;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL PROTOCOL; HUMAN; HYPERTENSION; LABORATORY TEST; PATIENT COMPLIANCE; PILL; PRACTICE GUIDELINE; PRIORITY JOURNAL; WORLD HEALTH ORGANIZATION; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; ECONOMICS; GLOBAL HEALTH; MORTALITY; ORGANIZATION; ORGANIZATION AND MANAGEMENT;

BLOOD PRESSURE MONITORING, AMBULATORY; CARDIOVASCULAR DISEASES; CLINICAL PROTOCOLS; GLOBAL HEALTH; HUMANS; HYPERTENSION; ORGANIZATIONS; TREATMENT ADHERENCE AND COMPLIANCE; WORLD HEALTH ORGANIZATION;

EID: 85051967453     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.13280     Document Type: Article

References (43)

1. Roth GA, Johnson C, Abajobir A, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol. 2017;71:1-25.
2. GBD 2013 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386:2287-2323.
3. Gaziano TA. Reducing the growing burden of cardiovascular disease in the developing world. Health Aff (Millwood). 2007;26:13-24.
4. Mills KT, Bundy JD, Kelly TN, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. 2016;134:441-450.
5. Padwal RS, Bienek A, McAlister FA, Campbell NR. Outcomes research task force of the Canadian Hypertension Education Program. Epidemiology of hypertension in Canada: an update. Can J Cardiol. 2016;32:687-694.
6. Luepker RV, Steffen LM, Jacobs DR Jr, Zhou X, Blackburn H. Trends in blood pressure and hypertension detection, treatment, and control 1980 to 2009: the Minnesota heart survey. Circulation. 2012;126:1852-1857.
7. Frieden TR, Bloomberg MR. Saving an additional 100 million lives. Lancet. 2018;391:709-712.
8. Frieden TR, King SM, Wright JS. Protocol-based treatment of hypertension: a critical step on the pathway to progress. JAMA. 2014;311:21-22.
9. Tran DN, Njuguna B, Mercer T, et al. Ensuring patient-centered access to cardiovascular disease medicines in low-income and middle-income countries through health-system strengthening. Cardiol Clin. 2017;35:125-134.
10. Ogedegbe G, Gyamfi J, Plange-Rhule J, et al. Task shifting interventions for cardiovascular risk reduction in low-income and middle-income countries: a systematic review of randomised controlled trials. BMJ Open. 2014;4:e005983.
11. Hamdidouche I, Jullien V, Boutouyrie P, Billaud E, Azizi M, Laurent S. Drug adherence in hypertension: from methodological issues to cardiovascular outcomes. J Hypertens. 2017;35:1133-1144.
12. Reboldi G, Gentile G, Angeli F, Verdecchia P. Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials. Vasc Health Risk Manag. 2009;5:411-427.
13. Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group. JAMA. 1979;242:2562-2571.
14. Feldman RD, Zou GY, Vandervoort MK, Wong CJ, Nelson SA, Feagan BG. A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension. 2009;53:646-653.
15. Stewart S, Stocks NP, Burrell LM, et al. More rigorous protocol adherence to intensive structured management improves blood pressure control in primary care: results from the Valsartan Intensified Primary carE Reduction of Blood Pressure study. J Hypertens. 2014;32:1342-1350.
16. Jaffe MG, Lee GA, Young JD, Sidney S, Go AS. Improved blood pressure control associated with a large-scale hypertension program. JAMA. 2013;310:699-705.
17. Ford N, Ball A, Baggaley R, et al. The WHO public health approach to HIV treatment and care: looking back and looking ahead. Lancet Infect Dis. 2018;18:e76-e86.
18. Frieden TR, Munsiff SS. The DOTS strategy for controlling the global tuberculosis epidemic. Clin Chest Med. 2005;26:197-205.
19. World Health Organization. HEARTS: Technical Package for Cardiovascular Disease Management in Primary Health Care. Geneva, Switzerland: World Health Organization; 2016.
20. Angell SY, De Cock KM, Frieden TR. A public health approach to global management of hypertension. Lancet. 2015;385:825-827.
21. Campbell NR, Berbari AE, Cloutier L, et al. Policy statement of the world hypertension league on noninvasive blood pressure measurement devices and blood pressure measurement in the clinical or community setting. J Clin Hypertens (Greenwich). 2014;16:320-322.
22. Frieden TR, Jaffe MG. Saving 100 million lives by improving global treatment of hypertension and reducing cardiovascular disease risk factors. J Clin Hypertens (Greenwich). 2018;20:208-211.
23. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/ AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017. https://doi.org/10.1161/hyp.0000000000000065. [Epub ahead of print]
24. Reboussin DM, Allen NB, Griswold ME, et al. Systematic review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2017; pii: HYP.0000000000000067. https://doi. org/10.1161/hyp.0000000000000067. [Epub ahead of print]
25. Feldman RD. Single pill combinations as initial therapy in the management of hypertension: What is taking you so long? Am J Hypertens. 2018;31:263-264.
26. Makani H, Bangalore S, Romero J, et al. Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate – a meta-analysis of randomized trials. J Hypertens. 2011;29:1270-1280.
27. Mancia G, Schumacher H. Incidence of adverse events with telmisartan compared with ACE inhibitors: evidence from a pooled analysis of clinical trials. Patient Prefer Adherence. 2012;6:9.
28. ONTARGET Investigators, Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-1559.
29. The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372:1174-1183.
30. Sica D. Calcium channel blocker-related peripheral edema: can it be resolved? J Clin Hypertens (Greenwich). 2003;5:291-295.
31. Chi C, Tai C, Bai B, et al. Angiotensin system blockade combined with calcium channel blockers is superior to other combinations in cardiovascular protection with similar blood pressure reduction: a meta-analysis in 20,451 hypertensive patients. J Clin Hypertens (Greenwich). 2016;18:801-808.
32. Mazzaglia G, Ambrosioni E, Alacqua M, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation. 2009;120:1598-1605.
33. Rao CR, Kamath VG, Shetty A, Kamath A. Treatment compliance among patients with hypertension and type 2 diabetes mellitus in a coastal population of southern India. Int J Prev Med. 2014;5:992-998.
34. Bandak G, Sang Y, Gasparini A, et al. Hyperkalemia after initiating renin-angiotensin system blockade: the Stockholm Creatinine Measurements (SCREAM) project. J Am Heart Assoc. 2017;6:pii: e005428.
35. Chang AR, Sang Y, Leddy J, et al. Antihypertensive medications and the prevalence of hyperkalemia in a large health system. Hypertension. 2016;67:1181-1188.
36. Franse LV, Pahor M, Di Bari M, Somes GW, Cushman WC, Applegate WB. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension. 2000;35:1025-1030.
37. ALLHAT Officers and Coordinators for the ALLHAT Collaborative. Research Group. The antihypertensive and lipid-lowering treatment to prevent heart attack trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2002;288:2981-2997.
38. World Health Organization. WHO Model List of Essential Medicines, 20th List. March 2017 (amended August 2017). Geneva, Switzerland: World Health Organization; 2017.
39. Wirtz VJ, Kaplan WA, Kwan GF, Laing RO. Access to medications for cardiovascular diseases in low-and middle-income countries. Circulation. 2016;133:2076-2085.
40. Kishore SP, Blank E, Heller DJ, et al. Modernizing the World Health Organization list of essential medicines for preventing and controlling cardiovascular diseases. J Am Coll Cardiol. 2018;71:564-574.
41. Farley TA, Dalal MA, Mostashari F, Frieden TR. Deaths preventable in the US by improvements in use of clinical preventive services. Am J Prev Med. 2010;38:600-609.
42. World Health Organization, Executive Board. Draft Thirteenth General Programme of Work, 2019-2023. Executive Board, 142nd session. EB142/3, 5 January 2018. Geneva, Switzerland: World Health Organization; 2018. http://apps.who.int/gb/ebwha/pdf_files/EB142/B142_3-en.pdf. Accessed April 5, 2018.
43. Ordunez P, Martinez R, Niebylski ML, Campbell NR. Hypertension prevention and control in Latin America and the Caribbean. J Clin Hypertens (Greenwich). 2015;17:499-502.